Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/210403
Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Several psychotropic drugs, including antidepressants (AD), mood stabilizers, and antipsychotics (AP) have been suggested to have favorable effects in the treatment of COVID-19. The aim of this systematic review and meta-analysis was to collect evidence from studies concerning the scientific evidence for the repurposing of psychotropic drugs in COVID-19 treatment. Two independent authors searched PubMed-MEDLINE, Scopus, PsycINFO, and ClinicalTrials.gov databases, and reviewed the reference lists of articles for eligible articles published up to 13th December, 2021. All computational, preclinical and clinical (observational and/or RCTs) studies on the effect of any psychotropic drug on Sars-CoV-2 or patients with COVID-19 were considered for inclusion. We conducted random effect meta-analyses on clinical studies reporting the effect of AD or AP on COVID-19 outcomes. 29 studies were included in the synthesis: 15 clinical, 9 preclinical, and 5 computational studies. 9 clinical studies could be included in the quantitative analyses. AD did not increase the risk of severe COVID-19 (RR= 1.71; CI 0.65-4.51) or mortality (RR=0.94; CI 0.81-1.09). Fluvoxamine was associated with a reduced risk of mortality for COVID-19 (OR=0.15; CI 0.02-0.95). AP increased the risk of severe COVID-19 (RR=3.66; CI 2.76-4.85) and mortality (OR=1.53; CI 1.15-2.03). Fluvoxamine might be a possible candidate for psychotropic drug repurposing in COVID-19 due to its anti-inflammatory and antiviral potential, while evidence on other AD is still controversial. Although AP are associated with worse COVID-19 outcomes, their use should be evaluated case to case and ongoing treatment with antipsychotics should be not discontinued in psychiatric patients.
Citació
Citació
GÓMEZ-RAMIRO, Marta, VIETA I PASCUAL, Eduard, FICO, Giovanna, ISAYEVA, Ulker, DE PRISCO, Michele, OLIVA, Vincenzo, SOLÉ CABEZUELO, Brisa, MONTEJO EGIDO, Laura, GRANDE I FULLANA, Iria, ARBELO, Néstor, PINTOR PÉREZ, Luis, CARPINIELLO, Bernardo, MANCHIA, Mirko, MURRU, Andrea, 2EPs Group. Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis. _European Neuropsychopharmacology_. 2022. Vol. 66, núm. 30-44. [consulta: 23 de gener de 2026]. ISSN: 0924-977X. [Disponible a: https://hdl.handle.net/2445/210403]